dexlansoprazole (dexilant) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain healing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.   NCATS

Chemistry

  • SMILES: CC1=C(OCC(F)(F)F)C=CN=C1C[S@@+]([O-])C2=NC3=C(N2)C=CC=C3
  • InChIKey: MJIHNNLFOKEZEW-RUZDIDTESA-N
  • Mol. Mass: 369.361
  • ALogP: 3.52
  • ChEMBL Molecule:
    dexlansoprazole  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$6.8910 - $9.8740
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole | dexilant | dexlansoprazole | dexlansoprazole sesquihydrate | doxirazole | kapidex | (r)-lansoprazole | r-lansoprazole | t-168390 | tak-114 | tak-390 | tak-390mr

Organizations (34)

Research & Development (31)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (3)


 

Esophagitis (approved 2009)

Gastroesophageal Reflux

Heartburn (approved 2009)

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Barrett Esophagus (Phase 4)

Biological Availability (Phase 1)

Bone and Bones (Phase 1)

Chest Pain (Phase 4)

Colitis, Ulcerative (Phase 2)

Deglutition Disorders (Phase 1/Phase 2)

Drugs, Generic (Phase 1)

Eosinophilic Esophagitis (Phase 1/Phase 2)

Esophagitis (Phase 3)

Esophagitis, Peptic (Phase 3)

Gastroesophageal Reflux (Phase 4)

Healthy Volunteers (Phase 1)

Heartburn (Phase 3)

Helicobacter pylori (Phase 4)

Homeostasis (Phase 1)

Inflammation (Phase 4)

Intestinal Neoplasms (Phase 4)

Laryngopharyngeal Reflux (Phase 4)

Pharmacology, Clinical (Phase 1)

Proton Pump Inhibitors (Phase 4)

Tonsillitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 56
  • # of Trial Organizations: 31

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue